| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
118,643 |
92,834 |
$4.28M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
25,744 |
22,488 |
$949K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
16,660 |
14,218 |
$639K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,746 |
16,583 |
$407K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,107 |
1,893 |
$178K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
13,716 |
11,009 |
$172K |
| 99205 |
Prolong outpt/office vis |
1,568 |
1,260 |
$121K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,107 |
907 |
$80K |
| 64483 |
|
685 |
541 |
$73K |
| 90791 |
Psychiatric diagnostic evaluation |
505 |
474 |
$36K |
| 99152 |
|
6,030 |
4,288 |
$33K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,190 |
516 |
$31K |
| 90834 |
Psychotherapy, 45 minutes with patient |
701 |
565 |
$30K |
| 62370 |
|
588 |
451 |
$18K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
619 |
266 |
$11K |
| 64484 |
|
202 |
164 |
$11K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
194 |
156 |
$7K |
| 62323 |
|
169 |
131 |
$6K |
| 64493 |
|
113 |
73 |
$6K |
| 20610 |
|
224 |
180 |
$5K |
| 99215 |
Prolong outpt/office vis |
301 |
171 |
$3K |
| 64494 |
|
100 |
61 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
491 |
190 |
$2K |
| 64635 |
|
15 |
13 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
236 |
91 |
$1K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
246 |
90 |
$1K |
| 76942 |
|
55 |
53 |
$1K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
180 |
61 |
$874.94 |
| 64636 |
|
15 |
13 |
$853.67 |
| 90832 |
Psychotherapy, 30 minutes with patient |
33 |
27 |
$782.47 |
| 97162 |
|
16 |
15 |
$771.76 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
179 |
64 |
$765.71 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
60 |
44 |
$714.24 |
| 72141 |
|
15 |
12 |
$544.56 |
| 62321 |
|
12 |
12 |
$430.65 |
| 62368 |
|
19 |
13 |
$359.33 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
407 |
298 |
$272.92 |
| 96130 |
|
12 |
12 |
$258.98 |
| 96131 |
|
12 |
12 |
$191.30 |
| J3360 |
Injection, diazepam, up to 5 mg |
191 |
77 |
$99.21 |
| 96138 |
|
12 |
12 |
$82.87 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
30 |
27 |
$73.54 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
92 |
79 |
$59.84 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
15 |
14 |
$51.62 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
89 |
78 |
$0.34 |
| 4004F |
|
150 |
115 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
2,331 |
1,763 |
$0.00 |
| 1125F |
|
188 |
148 |
$0.00 |
| 3008F |
|
156 |
118 |
$0.00 |
| 99406 |
|
43 |
26 |
$0.00 |